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Abstract
Background: Clinical outcome of patients with high-grade ccRCC (clear cell renal cell carcinoma) remains still poor
despite recent advances in treatment strategies. Molecular mechanism of pathogenesis in developing high-grade
ccRCC must be clarified. In the present study, we found that SAV1 was significantly downregulated with copy
number loss in high-grade ccRCCs. Therefore, we investigated the SAV1 function on cell proliferation and apoptosis
in vitro. Furthermore, we attempted to clarify the downstream signaling which is regulated by SAV1.
Methods: We performed array CGH and gene expression analysis of 8 RCC cell lines (786-O, 769-P, KMRC-1, KMRC-
2, KMRC-3, KMRC-20, TUHR4TKB, and Caki-2), and expression level of mRNA was confirmed by quantitative RT-PCR
(qRT-PCR) analysis. We next re-expressed SAV1 in 786-O cells, and analyzed its colony-forming activity. Then, we
transfected siRNAs of SAV1 into the kidney epithelial cell line HK2 and renal proximal tubule epithelial cells
(RPTECs), and analyzed their proliferation and apoptosis. Furthermore, the activity of YAP1, which is a downstream
molecule of SAV1, was evaluated by western blot analysis, reporter assay and immunohistochemical analysis.
Results: We found that SAV1, a component of the Hippo pathway, is frequently downregulated in high-grade
ccRCC. SAV1 is located on chromosome 14q22.1, where copy number loss had been observed in 7 of 12 high-
grade ccRCCs in our previous study, suggesting that gene copy number loss is responsible for the downregulation
of SAV1. Colony-forming activity by 786-O cells, which show homozygous loss of SAV1, was significantly reduced
when SAV1 was re-introduced exogenously. Knockdown of SAV1 promoted proliferation of HK2 and RPTEC.
Although the phosphorylation level of YAP1 was low in 786-O cells, it was elevated in SAV1-transduced 786-O cells.
Furthermore, the transcriptional activity of the YAP1 and TEAD3 complex was inhibited in SAV1-transduced 786-O
cells. Immunohistochemistry frequently demonstrated nuclear localization of YAP1 in ccRCC cases with SAV1
downregulation, and it was preferentially detected in high-grade ccRCC.
Conclusions: Taken together, downregulation of SAV1 and the consequent YAP1 activation are involved in the
pathogenesis of high-grade ccRCC. It is an attractive hypothesis that Hippo signaling could be candidates for new
therapeutic target.
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Renal cell carcinoma (RCC) is histopathologically sub-
divided into various categories, of which clear cell
renal cell carcinoma (ccRCC) is the most common
subtype, accounting for 70-80% of all RCCs [1]. Fuhr-
man’s nuclear grading system is used as a reliable
prognostic indicator for ccRCCs [2], and it is widely
accepted that the clinical outcome of patients with
high-grade ccRCC remains poor despite recent
advances in treatment strategies [3-6]. Therefore, it is
important to clarify the pathogenesis of high-grade
ccRCC in order to develop new treatments for improv-
ing the prognosis of affected patients. However, differ-
ences in the molecular mechanisms of pathogenesis
between low-grade and high-grade ccRCCs remain to
be determined.
We have previously reported the presence of chro-
mosomal copy number aberrations (CNAs) in ccRCC
determined using array-based CGH analysis [7]. In
our previous study, 14q loss was observed in 7 of 12
h i g h - g r a d ec c R C C s ,b u ti no n l y1o f1 0l o w - g r a d e
ccRCCs, suggesting that 14q loss is important for the
development of the former. Furthermore, we had pre-
viously found that genes located at 14q with copy
number loss tended to be downregulated, suggesting
that copy number loss at 14q in high-grade ccRCC is
responsible for the downregulation of genes located in
this region, and that putative tumor suppressor genes
may be present at this chromosomal locus [7]. How-
ever, the genes concerned at 14q have not yet been
identified.
In the present study, we attempted to identify genes
that are downregulated as a result of copy number loss
at 14q by using ccRCC cell lines in addition to clinical
samples. We found that the SAV1 gene, a human
homolog of salvador,w h i c hi sk n o w nt ob eat u m o r
suppressor in Drosophila [8], was significantly downre-
gulated in ccRCCs with 14q loss. Further analysis of
SAV1 function revealed that it is a putative tumor sup-
pressor gene in high-grade ccRCCs.
Methods
Cell culture
The renal cell carcinoma cell lines 786-O (#CRL-1932),
769-P (#CRL-1933) and Caki-2 (#HTB-47), and the
human cell line HK2 (#CRL-1427), were purchased from
the American Type Culture Collection (ATCC) (Rock-
ville, MD). KMRC-1, KMRC-2, KMRC-3, and KMRC-20
were purchased from JCRB (Osaka, Japan), and
TUHR4TKB was provided by RIKEN BRC through the
National Bio-Resource Project of MEXT, Japan. RPTEC
was purchased from Lonza Walkersville Inc. (Walkers-
ville, MD). All cell lines were maintained in accordance
with the supplier’s instructions.
Tissue samples and histopathological examination
Primary ccRCCs were surgically resected at Oita Univer-
sity Hospital, and diagnosed histopathologically as
described previously [7]. Information on the other 98
patients is summarized in Additional file 1: Table S1.
Use of the tissue samples for all experiments was
approved by all the patients and by Oita University
Ethics Committee (Approval No. P-05-05).
Immunohistochemistry
Immunohistochemistry of paraffin-embedded RCC tis-
sue sections was performed in a similar way to that
used in our previous work [9]. Anti-SAV1 antibody
(clone 3B320; Abnova, Taipei, Taiwan) and anti-YAP
antibody (Cell Signaling Technology, Danvers) were
used as the primary antibodies.
Quantitative RT-PCR
Quantitative RT-PCR was performed with a Universal
probe library (Roche Diagnostics, Mannheim, Germany)
and LightCycler 480 probe master (Roche Diagnostics)
by the Taqman method as described previously [10].
Levels of messenger RNA expression relative to KPNA6
were obtained from a standard curve. We used KPNA6
as a control in this study because KPNA6 expression
was not statistically different among the ccRCC and
non-neoplastic tissues, although expression levels of
known markers such as beta-2-microgloblin and glycer-
aldehydes 3-phosphate dehydrogenase (GAPDH) were
variable across the samples [11].
Lentiviral vector production and in vitro transduction
The full-length SAV1 cDNA was obtained from NBRC
(NITE Biological Resource Center, Chiba, Japan), cloned
into pLenti7.3/V5-DEST (Invitrogen, Carlsbad, CA,
USA) using the Gateway system
™ in accordance with
the manufacturer’s instructions, and used to generate
the vector SAV1-pLenti7.3/V5-DEST (pLenti-SAV1).
Transient transfections of the pLenti7.3/V5-DEST
empty vector and pLenti-SAV1 with ViraPower Packa-
ging Mix (Invitrogen) into HEK293T cells were per-
formed using Lipofectamine2000 (Invitrogen) in
accordance with the manufacturer’s instructions. After
48 h, the viral supernatants were collected, filtered, and
enriched by ultracentrifugation. Subsequently, transduc-
tion of target cells was performed at an optimized mul-
tiplicity of infection (MOI) of 5 with Polybrene at a final
concentration of 6.0 μg/ml. To identify stable clones of
SAV1-re-expressing cells, the full-length SAV1 cDNA
was cloned into pLenti6.3/V5-DEST (Invitrogen). Lenti-
virus expressing SAV1 was generated as described
above. 786-O cells were transduced with SAV1-
pLenti6.3/V5-DEST or the pLenti6.3/V5-DEST vector,
respectively. After transduction and selection with 0.5
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for SAV1 were obtained, and designated as SAV1-1 and
SAV1-2. Control cells were also generated using the
pLenti6.3/V5-DEST empty vector.
Colony formation assay
One day after transduction of 786-O or 769-P cells with
lentivirus expressing SAV1, one fiftieth of the cells were
reseeded on 100-mm dishes and cultured. When colo-
nies became visible, they were stained with Giemsa for
30 min, rinsed with water, and counted.
siRNA transfection
Cells were transfected with Stealth
™ RNAi oligonucleo-
tide or the Stealth
™ RNAi Negative Control Duplex
with the corresponding GC content (Invitrogen) at a
final concentration of 10 nM using Lipofectamine RNA-
MAX (Invitrogen) in accordance with the manufac-
turer’s instructions.
Proliferation assay
After transfection of siRNAs in a 96-well plate, MTS
assay was carried out using the CellTiter 96
RAQueous
One Solution Cell Proliferation Assay Kit (Promega,
Madison, WI, USA), and the optical density was mea-
sured at 492 nm using a fluorescence reader (Tecan
SpectraFluor) (Tecan, Crailsheim, Germany). In addition,
BrdU incorporation was performed using a Cell Prolifera-
tion ELISA Kit (Roche Applied Science, Mannheim, Ger-
many) in accordance with the manufacturer’s protocols.
Apoptosis assay
Cells were transfected with siRNA in a 96-well plate and
cultured for 72 h. Nuclear morphology was then evalu-
ated for apoptosis. DNA fragmentation was detected in
the 96-well format using Cell Death Detection ELISA
plus (Roche Applied Science) in accordance with the
manufacturer’s instructions. The activity of caspase 3
and caspase 7 was detected in the 96-well format by
using the caspase-Glo 3/7 Assay (Promega) according to
the manufacturer’s instructions.
Western blot analysis
Western blot analysis was performed similarly to that in
our previous study [12]. In each analysis, 10 μg of cell
lysate was used. The primary antibodies employed were:
anti-human GAPDH antibody (Sigma-Aldrich), anti-
SAV1 antibody (Cell Signaling Technology), anti-phos-
phorylated YAP antibody (Ser127; Cell Signaling Tech-
nology), and anti-YAP antibody (Santa Cruz
Biotechnology). Detection was performed with ECL
Western Blotting Detection Reagents (Amersham Bios-
ciences, Piscataway, NJ, USA) in accordance with the
manufacturer’s instructions.
Dual luciferase assay
For the luciferase reporter assay, stable clones of 786-O
cells (5 × 10
4) were seeded in 6-well plates, and then
co-transfected with 0.5 μg of pGL4.35 (9xUAS Gal4)
and GAL4-TEADs, respectively, using Lipofectamine
Plus (Invitrogen). At 48 h after transfection, the cells
were lysed and luciferase activity was assayed using a
Dual-luciferase Reporter Assay kit (Promega) in accor-
dance with the manufacturer’s instructions. All lucifer-
ase activities were normalized to the Renilla luciferase
reporter pRL-CMV plasmid (Promega).
Statistical analysis
Quantitative RT-PCR data were analyzed statistically by
the Mann-Whitney U-test. The two-sided Student’s t
test and Fisher’s exact test was used to analyze differ-
ences in experimental data obtained from the cell lines.
Differences at P < 0.05 were considered statistically
significant.
Additional methods are described in Supplementary
methods (Additional file 2: Methods S1)
Results
SAV1 is downregulated in RCCs with copy number loss at
14q22.1
We performed array CGH analysis and gene expression
analysis of 8 RCC cell lines (786-O, 769-P, KMRC-1,
KMRC-2, KMRC-3, KMRC-20, TUHR4TKB, and Caki-
2) in order to identify downregulated genes located in
the region of 14q loss (Additional file 3: Figure S1a, [7]).
All the data obtained in the array CGH and expression
microarray analysis are available at DDBJ via CIBEX
(http://cibex.nig.ac.jp/index.jsp), under accession num-
bers CBX97 for array CGH, and CBX96 for expression-
microarray. Copy number loss at 14q was detected in all
the cell lines analyzed. Detailed analysis of the region of
copy number loss at 14q revealed two different homozy-
gous deletions at 14q in 3 (786-O, 769-P, KMRC-1) of
the 8 cell lines.
In 786-O, a homozygous loss was detected at 14q22.1
(Additional file 3: Figure S1b), and this encompassed
three genes: SPG, SAV1, and MAP4K5 (Additional file 3:
Figure S1c). On the other hand, in 769-P and KMRC-1
cells, a homozygous loss was detected at 14q23.1, where
only the HIF-1a gene is located. Next, using array CGH
data and transcriptome data for these 8 cell lines, we
analyzed whether the expression levels of the SPG,
SAV1, MAP4K5,a n dHIF-1a genes were correlated with
their gene copy number status. As shown in Figure 1a,
the SAV1 gene showed a positive correlation between
t h ec o p yn u m b e rc h a n g ea n dt h ee x p r e s s i o nr a t i o( R=
0.8871; p < 0.005) (Figure 1a). In contrast, copy number
loss was not significantly correlated with the level of
mRNA expression for the SPG, MAP4K and HIF-1a
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Page 3 of 10genes (Additional file 4: Figure S2), suggesting that SAV1
downregulation is correlated with gene copy number loss
at 14q in these cell lines. To confirm this trend in ccRCC
cases, quantitative RT-PCR (qRT-PCR) analysis of ccRCC
samples was performed, and this revealed that the levels of
SAV1 mRNA in cases showing 14q loss (n = 10) were sig-
nificantly lower than those without 14q loss (n = 12) (p <
0.005), although they were similar between cases without
14q loss and normal kidney (Figure 1b). Furthermore,
qRT-PCR analysis of ccRCC samples revealed that the
levels of SAV1 mRNA in high-grade CCCs (n = 7) were
significantly lower than those in low-grade CCCs (n = 8)
and normal kidney (n = 5) (p < 0.005) (Figure 1c). In addi-
tion, protein level of SAV1 in ccRCC cases was evaluated
by immunohistochemistry. SAV1 protein was detected in
proximal renal tubules, podocytes, and endothelial cells in
normal tissues (Additional file 5: Figure S3). The specifi-
city of SAV1 antibody was confirmed by immunocyto-
chemistry of 786-O cells transduced with lentivirus
expressing SAV1 or control virus (Additional file 6: Figure
S4). In tumor cells, SAV1 downregulation at the protein
level was observed in 64 of the 98 ccRCC cases, and it was
correlated with tumor grade (Table 1). These findings sug-
gest that SAV1 is downregulated in RCC cell lines as well
as ccRCC samples and that its downregulation occurs pre-
ferentially in high-grade ccRCCs. To evaluate the SAV1
gene mutation, we performed PCR for 6 ccRCC cases with
SAV1 downregulation using 5 pairs of primers within
open reading frame and we could not detect any muta-
tions (data not shown), suggesting that gene mutation
does not contribute to SAV1 inactivation in RCC.
SAV1 inhibits colony formation and cell proliferation
We next re-expressed SAV1 in 786-O cells, in which
SAV1 is homozygously deleted, by transducing them
with SAV1 (Figure 2a), and analyzed their colony-form-
ing activity. As shown in Figure 2b, colony-forming
activity was significantly reduced in SAV1-transduced
786-O cells. Similar observations were obtained for 769-
P cells (Figure 2a, b). Furthe r m o r e ,t h i st r e n dw a sa l s o
confirmed by MTS assay (Additional file 7: Figure S5).
We next transfected small interfering RNAs (siRNAs),
designed to target distinct sites of SAV1 mRNA, into
the kidney epithelial cell line HK2 and renal proximal
tubule epithelial cells (RPTECs), and analyzed their pro-
liferation (Figure 3a). We found that cell proliferation
was promoted in HK2 and RPTECs transfected with
SAV1-siRNA (Figure 3b), whereas the cell cycle of HK2
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Figure 1 SAV1 is downregulated in RCC with copy number loss
at 14q22.1. a Positive correlation of copy number with the
expression ratio (R = 0.8871) of the SAV1 gene in RCC cell lines
(786-O, 769-P, KMRC-1, KMRC-2, KMRC-3, KMRC-20, TUHR4TKB, and
Caki-2). Log2 ratio of the normalized relative signal intensity of SAV1
by microarray (Y-axis) and log2 ratio of the gene copy number (X-
axis) are plotted for each cell line. R, Pearson correlation coefficient.
p-values were calculated by t test. b Correlation of the expression
level with copy number loss of SAV1 mRNA at 14q. Quantitative RT-
PCR was performed for ccRCC cases that had been analyzed by
array CGH in our previous study [7]. On the basis of gene copy
number ratio, ccRCC cases were divided into two groups [cases
without 14q loss; log2 ratio -0.14 to 0.15 (n = 10), and cases with
14q loss; log2 ratio < -0.14 (n = 12)] and analyzed for their
expression of SAV1. The box plots show the log2 ratio of SAV1
mRNA normalized by the median value for 6 samples of normal
kidney (Normal). SAV1 mRNA levels are significantly lower in cases
with 14q loss than in those without, and normal kidney (p < 0.005).
The Y-axis displays the expression level (log2). P values were
calculated by the Mann-Whitney U-test. *p < 0.005. Vertical lines in
each column indicate mean ratio, and bars show s.d.. c Correlation
of the expression level of SAV1 mRNA with tumor grade. The box
plots show log2 ratio of SAV1 mRNA normalized by the median
value for 6 samples of normal kidney. SAV1 mRNA levels are
significantly lower in high-grade ccRCC tissue than in low-grade
ccRCC and normal kidney (p < 0.005).
Table 1 Impact of SAV1 protein expression and nuclear
grade in ccRCC
SAV1 immunoreactivity
Positive weak or negative Total
nuclear low 16 17 33
grade high 18 47 65
total 34 64 98
Fisher’s exact test p = 0.0469
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Page 4 of 10cells was not affected by SAV1-siRNA transfection
(Additional file 8: Figure S6). However, the apoptotic
activity of HK2 cells transfected with SAV1-siRNA was
significantly reduced in cells transfected with SAV1-
siRNA in comparison with those transfected with the
control (Figure 3c), suggesting that SAV1 downregula-
tion inhibits apoptosis in renal tubule cells.
Downregulation of SAV1 activates YAP
It has been reported that SAV1 may function as a com-
ponent of the Hippo signaling pathway, and the Hippo
pathway targets the transcriptional co-activator YAP1
[13-17]. YAP1 is phosphorylated by LATS1/2, and the
phosphorylated YAP1 is then kept localized in the cyto-
plasm. On the other hand, when Hippo signaling is
inhibited, unphosphorylated YAP1 accumulates in the
nucleus, where it forms a transcriptionally active com-
plex with the transcription factor, TEAD [18,19]. To
determine whether Hippo signaling is actually inhibited
in RCCs in which SAV1 is frequently downregulated, we
analyzed the phosphorylation status of YAP1 in 786-O
and 769-P cells in which SAV1 are downregulated and
HK2 cells in which SAV1 is expressed at a comparable
level (Figure 4a). As shown in Figure 4a, phosphorylated
YAP1 was significantly decreased in 786-O and 769-P
cells, relative to HK2 cells. Furthermore, YAP1 phos-
phorylation was enhanced when SAV1 was re-expressed
in 786-O cells (Figure 4b).
It has been reported that unphosphorylated YAP1
binds to members of the TEAD family, including
TEAD1, 2, 3 and 4, and plays a functional role as a tran-
scriptional co-activator [17]. Therefore, we next exam-
ined whether SAV1 affects the transcriptional activity of
the YAP1-TEAD complex in RCCs. SAV1-transduced
786-O cells were transfected with expression plasmids
encoding a Gal4 DNA binding domain fused to TEAD1,
TEAD2, and TEAD3 (Gal4-TEADs), a Gal4-9x UAS
luciferase reporter (pGL4.31) and pRL-CMV (Figure 4c)
(Additional file 9: Figure S7). In control cells, co-trans-
fection of the Gal4-TEAD3 and Gal4-9x UAS luciferase
reporter led to an increase in luciferase activity. On the
other hand, in SAV1-transduced 786-O cells, the lucifer-
ase activity eventually decreased, suggesting that, in
RCCs with suppression of Hippo signaling, YAP1 activ-
ity is significantly elevated (Figure 4c).
To further confirm whether intracellular localization
of YAP1 is under the control of Hippo signaling, we
immunohistochemically analyzed the 98 cases of ccRCC
for expression of YAP1. We compared the intracellular
localization of YAP1 between ccRCCs showing downre-
gulation of SAV1 and those without SAV1 downregula-
tion. As shown in Figure 5 and Table 2, nuclear
localization of YAP1 was more frequently detectable in
ccRCCs with SAV1 downregulation than in those with-
out, suggesting that SAV1 downregulation leads to
nuclear translocation of YAP1. When we evaluated the
correlation between nuclear localization of YAP1 and
tumor grade, nuclear localization of YAP1 was preferen-
tially detected in high-grade (Table 3), suggesting that
the suppression of Hippo signaling through SAV1
downregulation tends to occur in high-grade ccRCCs.
Discussion
The Hippo pathway is known to control organ size both
in Drosophila and mammalian tissues, and many studies
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Figure 2 Re-expression of SAV1 inhibits cell proliferation and
colony formation. a SAV1 protein is expressed in 786-O and 769-P
cells transduced with SAV1. Total cell lysates were subjected to
Western blot analysis using anti-SAV1 antibody and anti-GAPDH
antibody, respectively. SAV1 protein was detected in SAV1-
transduced 786-O and 769-P cells (SAV1), but not in cells
transduced with pLenti7.3/V5 empty vector (control). b Re-
expression of SAV1 inhibits colony-formation in 786-O and 769-P
cells. Upper column; colony-forming activities of 786-O and 769-P
cells transduced with control vector or pLenti-SAV1. Colony
numbers were significantly reduced in 786-O and 769-P cells
transduced with pLenti-SAV1 (SAV1) compared with those
transduced with pLenti7.3/V5 (control). Experiments were performed
in triplicate. Lower column; A representative result of colony
formation assay using 786-O cells transduced with the control
vector and those transduced with SAV1.
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Page 5 of 10of the tumor suppressor function of the Hippo pathway
have been reported [13,17,20-22]. In the present study,
we found that SAV1 downregulation caused by 14q loss
conferred a survival and growth advantage on RCCs. It
has already been reported that the SAV1 gene is homo-
zygously deleted in two RCC cell lines [8]. However, it
has not been clarified whether the same abnormalities
actually occur in patients with RCCs. Therefore, our
present data appear to provide strong support for the
hypothesis that the SAV1 gene may be a potential
tumor suppressor of RCC. Furthermore, SAV1 has been
reported to act as a tumor suppressor in cancers other
than RCC. For example, two groups have recently
reported that conditional knockout mice, in which the
SAV1 gene was deleted only in the liver, developed
hepatocellular carcinoma (HCC) [23,24], suggesting that
deletion of the SAV1 gene is responsible for the devel-
opment of such carcinomas. Therefore, we propose that
SAV1
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Figure 3 Knockdown of SAV1 induces cell proliferation and inhibits apoptosis. a Expression of SAV1 protein was suppressed in HK2 cells
and RPTEC transfected with specific siRNAs. Two independent Stealth
™ RNAi oligonucleotides for SAV1 (SAV1-siRNA1 and SAV1-siRNA2), or the
Stealth
™ RNAi Negative Control Duplex siRNAs (control-siRNA) were transfected into HK2 and RPTEC cells. After 72 h, protein was extracted and
analyzed by Western blotting with anti-SAV1 antibody and anti-GAPDH antibody. SAV1 was markedly downregulated in HK2 and RPTEC cells
transfected with SAV1-siRNA1 and SAV1-siRNA2. b Knockdown of SAV1 induces proliferation of HK2 cells and RPTEC. Upper column; MTS assay at
72 h after transfection. Y axis indicates the absorbance at 492 nm for MTS assay. Experiments were performed in triplicate, and bars indicate s.d..
* p < 0.05; Student’s t test. Lower column; BrdU incorporation was estimated as the absorbance of cells transfected with SAV1-siRNA1 and SAV1-
siRNA2, and those transfected with control siRNA. Experiments were performed in triplicate, and bars indicate s.d.. * p < 0.05; Student’s t test.
MTS assay as well as BrdU incorporation demonstrated that proliferation of HK2 cells and RPTEC transfected with SAV1-siRNA1 and SAV1-siRNA2
was significantly increased relative to cells transfected with control siRNA. c Apoptotic activity after transfection with SAV1 siRNAs was
significantly inhibited. Upper column; HK2 cells transfected with control siRNA, SAV1-siRNA1 and SAV1-siRNA2 were incubated for 72 h and then
analyzed using a cell death ELISA kit. Y axis indicates the relative ratio of the absorbance at 492 nm for control cells set at 1.0. The results are
shown as means ± s.d. of three independent experiments. * p < 0.001; Student’s t test. Lower column; HK2 cells transfected with control siRNA,
SAV1-siRNA1 and SAV1-siRNA2 were incubated for 72 h and then analyzed using a Caspase-Glo 3/7 Assay kit. Y axis indicates the relative ratio of
the fluorescent signal for control cells set at 1.0. The results are shown as means ± s.d. of three independent experiments. *p < 0.001; Student’s t
test.
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Page 6 of 10the SAV1 gene is also involved in tumorigenesis of
ccRCC.
In the present study, we found that knockdown of
SAV1 induced significant inhibition of apoptosis in
immortalized kidney cell line, HK2. It has previously
been reported that apoptosis was inhibited in sav-
mutated eye imaginal disc of Drosophilla [8]. Further-
more, in SAV1 gene-disrupted mice, apoptotic keratino-
cytes of epidermis was found to be significantly reduced
compared with wild type mice [25]. Thus, on the basis
of our present data in addition to the previous reports,
it is suggested that downregulation of SAV1 may play
an important role in inhibiting apoptosis in RCC.
On the other hand, in the present study, the increase
of cell proliferation by SAV1 downregulation was rela-
tively modest. With respect to interpretation of this
r e s u l t ,w ec a n n o tr u l eo u tt h ep o s s i b i l i t yt h a tt h ed a t a
indicating the increase of cell proliferation shown by
MTS assay and BrdU-incorporation study may be
affected by the significant inhibition of apoptosis caused
by SAV1 knockdown. It has been reported that BrdU
incorporation was significantly increased in liver of
SAV1 gene-disrupted mice [24]. However, another
group has reported that the increase of proliferation of
embryonic keratinocytes isolated from SAV1-null mice
was comparable to that of wild type [25]. Further study
is needed to clarify whether SAV1 downregulation is
really responsible for cell proliferation in RCC.
We have previously reported that loss of 14q was
observed more frequently in cases of high-grade ccRCC
than in low-grade ccRCC [7]. Since it has been reported
that the prognosis of patients with high-grade ccRCCs is
markedly poor, loss of 14q is suggested to be involved
in the malignant phenotype of high-grade ccRCC [7]. In
the present study, SAV1 downregulation was confined
to high-grade ccRCCs with copy number loss at 14q
encompassing 14q22.1. Although we cannot rule out the
possibility that tumor suppressor genes other than
SAV1 may exist at 14q, we speculate that suppression of
the Hippo pathway caused by downregulation of SAV1
is involved in the development of high-grade ccRCCs.
It has been reported that YAP1 is a transcriptional
regulator and acts as a oncoprotein in various carcino-
mas [26-30]. Indeed, when YAP1 is hypophosphorylated
due to suppression of the Hippo signaling pathway
including SAV1, it translocates from the cytoplasm to
the nucleus and binds to various transcription factors
[16,17,25]. An experiment using conditional knockout
mice in which the SAV1 gene was deleted only in the
liver and YAP1 was specifically activated in oval cells
has clearly shown that SAV1 is required for inactivation
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Figure 4 Downregulation of SAV1 activates YAP1. a
Phosphorylation of YAP1 was decreased in RCC cell lines.
Phosphorylation of YAP1 in HK2, 786-O and 769-P cells was
analyzed by Western blot analysis with anti-phospho-YAP antibody,
anti-YAP antibody, and anti-GAPDH antibody, respectively. Protein
level of SAV1 in each cell line was demonstrated with anti-SAV1
antibody. SAV1 was detectable only in HK2 cells. b Phosphorylated
YAP1 is increased in SAV1-transduced 786-O cells. 786-O cells were
transduced with pLenti6.3/V5-DEST empty vector or SAV1-pLenti6.3/
V5-DEST, and one clone of control cells (designated as the control)
and two independent clones of SAV1-re-expressing cells (designated
as SAV1-1 and SAV1-2) were established. Western blotting was
performed with anti-phospho-YAP antibody, anti-YAP antibody, anti-
SAV1 antibody and anti-GAPDH antibody, respectively. c SAV1
suppresses transcriptional activity of YAP1-TEAD3. SAV1-1, SAV1-2
and control cells were transfected with the Gal4-TEAD3 plasmid
vector that expresses TEAD3 fused to GAL4 (kindly provided by Dr.
B. Zhao [19]), Gal4-9x UAS luciferase reporter (pGL4.31), and pRL-
CMV. Firefly luciferase activity was normalized to Renilla luciferase
activity. Normalized luciferase activity in control cells untransfected
with TEAD3 was set at 1. In SAV1-1 and SAV1-2 cells, the luciferase
activity was significantly decreased. Experiments were performed in
triplicate. The dual luciferase data are shown as mean ± SD. *p <
0.005 *; Student’s t test.
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Page 7 of 10of YAP1 [23]. In the present study, we found that phos-
phorylation of YAP1 was suppressed in SAV1-deficient
RCC cell lines and that phosphorylation of YAP1 was
enhanced in 786-O cells when SAV1 was re-expressed.
Furthermore, YAP1 tended to translocate to the nucleus
in SAV1-downregulated ccRCCs as well as in high-grade
ccRCCs. These findings suggest that activation of YAP1
due to downregulation of SAV1 is involved in the
pathogenesis of high-grade ccRCCs.
Recently, Zhao et al. reported that the transcription
factor TEAD binds to YAP, and that the resulting
YAP1-TEAD complex is required for YAP-induced cell
growth and epithelial mesenchymal transition (EMT)
[17]. We found that the transcriptional activity of
TEAD-YAP was repressed when SAV1 was re-expressed
in SAV1-deficient 786-O cells, suggesting that TEAD-
YAP may play functional roles in the regulation of cell
proliferation in RCC. However, at this stage, the
transcriptional targets of the TEAD-YAP transcription
factor complex in RCCs are still unclear. In order to
clarify the molecular mechanisms involved in the devel-
opment of high-grade RCCs, it will be necessary to iden-
tify the transcriptional target genes of the TEAD-YAP1
complex in RCCs. Because the prognosis of patients
with high-grade ccRCC remains poor, it is an attractive
hypothesis that unidentified molecules that are activated
by suppressed Hippo signaling could be candidates for
consideration in the development of new therapeutic
drugs for high-grade ccRCCs. Further studies will be
required to address this possibility.
Conclusions
We show that SAV1, a component of the Hippo path-
way, was frequently downregulated in high-grade ccRCC
in association with copy number loss of chromosome
14q22.1, where the SAV1 gene is located. In addition to
DBTF
DBTF
SAV1 YAP1  IgG
Figure 5 Nuclear localization of YAP1 is frequently detectable in ccRCCs with SAV1 downregulation. Immunohistochemistry of ccRCC
tissues using anti-SAV1 antibody and anti-YAP1 antibody (×400). Representative results are shown. YAP1 tends to be localized in the nucleus of
tumor cells in cases showing downregulation of SAV1 (case #96), whereas it tends to be localized mainly in the cytoplasm of tumor cells
without downregulation of SAV1 (case #84). The cytoplasm of endothelial cells is positively immunostained. No positive staining is detectable in
both cases using normal mouse IgG as the primary antibody (IgG).
Table 2 Immunohistochemical staining of SAV1 and YAP1
protein in ccRCC
SAV1 immunoreactivity
positive weak or negative Total
YAP1 Cytoplasmic pattern* 28 9 37
Nuclear pattern** 7 31 38
total 35 40 75
Fisher’s exact test p < 0.001
*Cytoplasmic pattern; YAP1 is mainly localized in cytoplasm of tumor
**Nuclear pattern; YAP1 is mainly localized in nucleus of tumor cells
Table 3 Impact of subcellular localization of YAP1 protein
and nuclear grade in ccRCC
nuclear grade
low high total
YAP1 Cytoplasmic pattern* 15 22 37
Nuclear pattern** 7 31 38
total 22 53 75
Fisher’s exact test p = 0.0445
*Cytoplasmic pattern; YAP1 is mainly localized in cytoplasm of tumor
**Nuclear pattern; YAP1 is mainly localized in nucleus of tumor cells
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Page 8 of 10these studies using ccRCC samples, we examined the
functional significance of SAV1 in cell lines. The results
indicated that the downregulation of SAV1 promoted
cell proliferation and inhibited apoptosis in ccRCC. In
addition, YAP1 tended to be located in the nucleus in
ccRCC cases with SAV1 downregulation, and it was pre-
ferentially detected in high-grade ccRCC. On the bases
of these findings, downregulation of SAV1 and the con-
sequent YAP1 activation are involved in the pathogen-
esis of high-grade ccRCC.
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